Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Chian‐Wei Chen"'
Autor:
Chien‐Yu Lin, Chia‐Hao Hu, Chia‐Fu Hsu, Jeng‐Shiuan Tsai, Chian‐Wei Chen, Chia‐Yin Lin, Chao‐Chun Chang, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin
Publikováno v:
Thoracic Cancer, Vol 14, Iss 19, Pp 1857-1864 (2023)
Abstract Background Some prospective studies have shown that second‐generation tyrosine kinase inhibitors (TKIs) provide better control in patients with non‐small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) muta
Externí odkaz:
https://doaj.org/article/7e94a69bce074dac9987c9d9a0641cf8
Autor:
Chin-Wei Kuo, Po-Lan Su, Tang-Hsiu Huang, Chien-Chung Lin, Chian-Wei Chen, Jeng-Shiuan Tsai, Xin-Min Liao, Tzu-Yi Chan, Chi-Chang Shieh
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Alveolar macrophages (AMs) are the drivers of pulmonary cytokine storm in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to investigate clinical–regulatory factors for the entrance protein of SARS-
Externí odkaz:
https://doaj.org/article/8979b424ecc844029895d652098ff14d
Autor:
Chang-Yao Chu, Chien-Yu Lin, Chien-Chung Lin, Chien-Feng Li, Shang-Yin Wu, Jeng-Shiuan Tsai, Szu-Chun Yang, Chian-Wei Chen, Chia-Yin Lin, Chao-Chun Chang, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su, Wu-Chou Su
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract The role of Programmed Cell Death Ligand 1 (PD-L1) expression in predicting epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) efficacy remains controversial. Recent studies have highlighted that tumor-intrinsic PD-L1 sig
Externí odkaz:
https://doaj.org/article/83cd94bc8c05488fbcc304f0efe0162e
Autor:
Chin-Wei Kuo, Chien-Yu Lin, Sheng-Huan Wei, Yun-Tse Chou, Chian-Wei Chen, Jeng-Shiuan Tsai, Po-Lan Su, Chien-Chung Lin
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Invasive pulmonary aspergillosis (IPA) can negatively impact cancer patients’ survival. It remains uncertain whether IPA’s impact on patient outcomes varies by treatment approach in advanced lung cancer. Objectives: To explore the ass
Externí odkaz:
https://doaj.org/article/e5f40e36b0f44c21a944f1256d1f3e63
Autor:
Chian-Wei Chen, Chien-Yu Lin, Jeng-Shiuan Tsai, Chia-Yin Lin, Chao-Chun Chang, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su, Chien-Chung Lin
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Although combination therapy including chemotherapy and immune checkpoint inhibitors (ICIs) improves overall survival (OS) of patients with non-small-cell lung cancer (NSCLC), there is a higher incidence of adverse events and treatment discontinuatio
Externí odkaz:
https://doaj.org/article/784fdc84b5bb4aefad8eabe1f2ae8ca2
Autor:
Po-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, Yi-Lin Chen, Wan-Li Chen, Kuan-Yu Lin, Chung-Liang Ho, Jeng-Shiuan Tsai, Szu-Chun Yang, Chian-Wei Chen, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin, Wu-Chou Su
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC). This study aimed to assess whether the presence of targetable driver mut
Externí odkaz:
https://doaj.org/article/249de0c14737440c9d0617b01e951b12
Autor:
Sheng‐Yuan Wang, Ching‐Han Lai, Chian‐Wei Chen, Szu‐Chun Yang, Chao‐Chun Chang, Chia‐Ying Lin, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin, Wu‐Chou Su
Publikováno v:
Thoracic Cancer, Vol 13, Iss 2, Pp 182-189 (2022)
Abstract Background Although epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have been the standard treatment for advanced EGFR‐mutant adenocarcinoma, the effects of upfront EGFR‐TKI use in unresectable stage III EGFR
Externí odkaz:
https://doaj.org/article/3354d277b5de4bd3b62e3690eae5a5b5
Autor:
Sheng-Han Tsai, Chia-Yin Shih, Chin-Wei Kuo, Xin-Min Liao, Peng-Chan Lin, Chian-Wei Chen, Tzuen-Ren Hsiue, Chiung-Zuei Chen
Publikováno v:
npj Primary Care Respiratory Medicine, Vol 32, Iss 1, Pp 1-6 (2022)
Abstract The primary barrier to initiating palliative care for advanced COPD patients is the unpredictable course of the disease. We enroll 752 COPD patients into the study and validate the prediction tools for 1-year mortality using the current guid
Externí odkaz:
https://doaj.org/article/df9b7c4186c04c18a9468c265f2cf7ef
Autor:
Tang-Hsiu Huang, Chin-Wei Kuo, Chian-Wei Chen, Yau-Lin Tseng, Chao-Liang Wu, Sheng-Hsiang Lin
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background Nintedanib is effective for treating idiopathic pulmonary fibrosis (IPF), but some patients may exhibit a suboptimal response and develop on-treatment acute exacerbation (AE-IPF), hepatic injury, or mortality. It remains unclear w
Externí odkaz:
https://doaj.org/article/2491455cfb9d4a70bcaa273ffdd29110
Publikováno v:
Thoracic Cancer, Vol 12, Iss 3, Pp 287-296 (2021)
Abstract Background Few studies have compared the efficacy of the irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), afatinib, with that of reversible EGFR‐TKIs. Therefore, this study assessed the effectiveness of
Externí odkaz:
https://doaj.org/article/6671e48806ba4583b0f96152a24d8692